Table 1.
Clinical trials. The table represents some examples for antibodies and immunotherapies, tested in ovarian cancer patients to target specifically the TME
| Drug name | Mechanism of action | Trials |
|---|---|---|
| Bevacizumab | Monoclonal antibody against vascular endothelial growth factor (VEGF) | Phase 2: in recurrent ovarian cancer patients (NCT01305213) |
| Siltuximab | Antibody against IL-6 | Phase 1/2: in patients with solid tumors, including ovarian cancer (NCT00841191) |
| Tocilizumab | Antibody against IL-6 receptor | Phase 1: combination with chemotherapy in recurrent epithelial ovarian cancer (NCT01637532) |
| Nivolumab | Anti-PD-1 antibody | Phase 1: combination with WT1 vaccine in recurrent ovarian cancer (NCT02737787) |
| Nivolomab and Ipilimab | Anti-PD-1 antibody and CTLA-4 antibody | Phase 2: combination of immune check point inhibitors in ovarian cancer, breast cancer and gastric cancer (NCT03342417) |
| Pembrolizumab | Anti-PD-1 antibody | Phase 2: Pembrolizumab following weekly Paclitaxel treatment for Platinum-resistant ovarian, fallopian tube or peritoneal cancer (NCT03430700) |
| Pembrolizumab with Gemcitabin and Cisplatin | Anti-PD-1 antibody | Phase 2: in recurrent Platinum-resistant ovarian cancer (NCT02608684) |
| NK immunotherapy | Natural Killer (NK) cells | Phase1/2: combination with cryotherapy in recurrent ovarian cancer (NCT02849353) |
| V3-OVA vaccine | Immunotherapy with a vaccine containing ovarian cancer antigens | Phase 2: in ovarian cancer patients (NCT03556566) |
| Autologous monocytes | Immunotherapy | Phase 1: combination with Sylatron(R) (Peginterferon alfa-2b) and Actimmune(R) (Interferon gamma-1b) in ovarian cancer (NCT02948426) |
| Plerixafor | Immunostimulant to mobilize hematopoietic stem cells | Phase 1: in high-grade serous ovarian, advanced pancreatic and colorectal adenocarcinomas (NCT03277209) |
| Rintatolimod with pembrolizumab and cisplatin |
Rintatolimod: immunomodulatory double strained RNA Pembrolizumab: anti-PD-1 antibody |
Phase 1/2: in recurrent ovarian cancer (NCT03734692) |
| Tremelimumab with Oplaparib | Anti-CTLA-4 antibody and PARP inhibitor | Phase 2: in recurrent ovarian, fallopian tube or peritoneal cancer (NCT04034927) |